Liquidia Corporation (LQDA)

Market Cap	1.05B
Revenue (ttm)	17.49M
Net Income (ttm)	-78.50M
Shares Out	76.03M
EPS (ttm)	-1.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	658,974
Open	13.86
Previous Close	13.86
Day's Range	13.56 - 14.24
52-Week Range	5.71 - 16.99
Beta	0.19
Analysts	Strong Buy
Price Target	21.60 (+56.41%)
Earnings Date	May 2, 2024

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement w...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 26, 2018
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: LQDA

Financial Performance

In 2023, Liquidia's revenue was $17.49 million, an increase of 9.75% compared to the previous year's $15.94 million. Losses were -$78.50 million, 91.4% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price forecast is $21.6, which is an increase of 56.41% from the latest price.

Price Target

$21.6

(56.41% upside)

Analyst Consensus: Strong Buy